Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e472e52510b9a0150fb8bb983e5c5a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-323 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65583 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
filingDate |
2012-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_896539bbc0e3d1e0b591010f31e32cad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37e6755e64e986ee6db5a76d2b2ef19f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a72e3b8eb555ccae9f3490889223ae5 |
publicationDate |
2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10066228-B2 |
titleOfInvention |
Oligonucleotides for treating expanded repeat diseases |
abstract |
The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11260073-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10905709-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019100755-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11674139-B2 |
priorityDate |
2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |